Emcure Pharmaceuticals FY26 Revenue Crosses $1 Bn, Up 16.6% to ₹9,204 Crore
Emcure Pharmaceuticals reported FY26 revenue of ₹9,204 crore, a 16.6% increase, crossing the US$1 billion mark. Q4 FY26 revenue was ₹2,470 crore (up 16.7%). Adjusted PAT grew over 40% for FY26. Strategic initiatives included Zuventus consolidation and European/Canadian acquisitions. International business grew 22.2%.
The announcement includes significant financial performance metrics, strategic business developments like acquisitions and partnerships, and achievement of major revenue milestones, which are highly material to investors.
The company reported strong revenue growth, crossing the US$1 billion milestone, and significant increases in profit margins and Adjusted PAT. Strategic acquisitions and partnerships also indicate positive future prospects.
Emcure Pharmaceuticals Limited announced its audited consolidated and standalone financial results for the quarter and year ended March 31, 2026. The company achieved a significant milestone by crossing US$1 billion in revenue, with a reported revenue growth of 16.6% to ₹9,204 crore for FY26.
For the fourth quarter of FY26, Emcure reported a revenue of ₹2,470 crore, marking a 16.7% year-on-year growth. The EBITDA for the quarter stood at ₹485 crore with a margin of 19.7%, while the Adjusted Profit After Tax (PAT) was ₹279 crore with a margin of 11.3%. For the full fiscal year FY26, revenue grew by 16.6% to ₹9,204 crore, with EBITDA at ₹1,789 crore (19.4% margin) and Adjusted PAT at ₹1,008 crore (10.9% margin).
The company highlighted strong performance in international markets, which grew by 22.2% to ₹5,177 crore, contributing 60% to the total revenue. Key strategic developments during the year included the full consolidation of Zuventus, acquisitions of Manx and Cutimed in Europe and Canada, and expanded partnerships with Novo Nordisk, Sanofi, and Roche.
R&D progress was noted, with the Biosimilar Bevacizumab receiving CDSCO endorsement and the HIV drug Lenacapavir's DMF filing. The company also reported an increase in R&D expenditure to ₹434 crore in FY26 and a significant reduction in Net Debt to EBITDA ratio to 0.6x.
What to do with a filing like this
Emcure Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.